Artery Therapeutics

Artery Therapeutics is a private clinical-stage biotechnology company developing peptide therapeutics for neurodegenerative diseases, with a primary focus on APOE4-associated Alzheimer's disease and related dementias. The company's core approach is based on an ApoE-derived peptide library designed to agonize the ABCA1 transporter and restore lipid transport biology implicated in APOE4-driven disease. Its lead program, CS6253, has generated Phase 1 human safety and pharmacokinetic data and is being advanced into a Phase 2A study in early-stage Alzheimer's patients who carry the APOE4 variant. Artery also positions its ABCA1-based approach as potentially relevant to Lewy body dementia and traumatic brain injury. The company is headquartered in the San Francisco Bay Area and has received support from NIH-NIA and the Alzheimer's Association.